ROCÍO
GARCÍA CARBONERO
Profesora asociada de Ciencias de la Salud
Universitat de Barcelona
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Universitat de Barcelona (16)
2023
-
Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours
European Journal of Cancer, Vol. 188, pp. 39-48
2022
-
Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors
Journal for immunotherapy of cancer, Vol. 10, Núm. 3
2021
-
Description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumab
Scientific Reports, Vol. 11, Núm. 1
-
Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study
Annals of Oncology, Vol. 32, Núm. 5, pp. 600-608
-
Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas
Clinical and Translational Oncology, Vol. 23, Núm. 10, pp. 1995-2019
2020
-
Comprehensive Characterization of the Mutational Landscape in Localized Anal Squamous Cell Carcinoma
Translational Oncology, Vol. 13, Núm. 7
-
Genetic profile and functional proteomics of anal squamous cell carcinoma: Proposal for a molecular classification
Molecular and Cellular Proteomics, Vol. 19, Núm. 4, pp. 690-700
-
VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02)
Cancer Medicine, Vol. 9, Núm. 3, pp. 1008-1016
2019
-
Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy before Standard Chemoradiotherapy and Surgery in Patients with High-Risk Rectal Adenocarcinoma: The GEMCAD 1402 Randomized Clinical Trial
JAMA Oncology, Vol. 5, Núm. 11, pp. 1566-1573
-
Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy
Annals of Oncology, Vol. 30, Núm. 3, pp. 439-446
2018
-
Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors
Oncologist, Vol. 23, Núm. 7, pp. 766-e90
2017
-
Optimization of RAS/BRAF mutational analysis confirms improvement in patient selection for clinical benefit to anti-EGFR treatment in metastatic colorectal cancer
Molecular Cancer Therapeutics, Vol. 16, Núm. 9, pp. 1999-2007
-
Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection
Journal for ImmunoTherapy of Cancer, Vol. 5, Núm. 1
-
Translational research in neuroendocrine tumors: Pitfalls and opportunities
Oncogene, Vol. 36, Núm. 14, pp. 1899-1907
2013
2010
-
Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): Results from the National Cancer Registry of Spain (RGETNE)
Annals of Oncology, Vol. 21, Núm. 9, pp. 1794-1803